Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
IMV Inc. (the "Company" or "IMV") (NASDAQ:IMV, TSX:IMV), a clinical-stage biopharmaceutical Company developing ...
IMV Inc. ("IMV" or the "Company") (NASDAQ:IMV, TSX:IMV), a clinical-stage company developing a portfolio of imm...
IMV Inc. (Nasdaq: IMV; TSX: IMV) today outlined its planned 2023 milestones to advance the clinical development of its lead the...
HC Wainwright & Co. analyst Joseph Pantginis maintains IMV (NASDAQ:IMV) with a Buy, adjusts price target to $65 - 1-for-10 ...
Complete responses were observed in patients who received at least three previous lines of treatment (including CAR-T's) R...
IMV Inc. (the "Corporation" or "IMV") (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company devel...
Combination of MVP-S/CPA and pembrolizumab showed encouraging clinical activity in advanced, metastatic bladder cancer patients...
IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its no...
IMV Inc.
